Department of Health and Aged Care (Australia), 3 May 2023 The Australian Government is delivering on its commitment to eliminate HIV transmission in Australia, and address the health disparities experienced by LGBTIQA+ people. An additional $19.7 million in the 2023–24 Budget will ensure better access to HIV testing, treatment and information, including support for the HIV workforce and to...
Update: Changes to HIV treatment access for people ineligible for Medicare
NAPWHA, ASHM, AFAO, May 2022 From 1st July, people with HIV who are ineligible for Medicare, and who previously received HIV medication through compassionate access schemes, will be required to transition to alternative access arrangements in order to receive government-funded treatment*. Option 1: individuals will need to engage in care with a public hospital-based physician and have their...
Agenda 2025: Ending HIV transmission in Australia in four years
Australian Federation of AIDS Organisations (AFAO), 17th June 2021 Agenda 2025 is a fully costed plan which draws upon evidence based research and is backed by top researchers, leaders, and clinicians in Australia’s community-led HIV response. Australia can end HIV transmission within four short years, averting over 6,000 infections by 2030 and saving $1.4 billion in health costs, according to a...
New digital factsheets for Aboriginal and Torres Strait Islander communities
Anwernekenhe National HIV Alliance (ANA) and ‘Australian Federation of AIDS Organisations (AFAO), June 2021 The Anwernekenhe National HIV Alliance (ANA) and AFAO are very excited to bring you these new digital factsheets for Aboriginal and Torres Strait Islander communities on PrEP, PEP, treatment as prevention, and HIV testing. Representatives from ANA and our other member organisations...
HIV in Australia 2021: infographics
AFAO, December 1st, 2020 Each year, AFAO develops the ‘HIV in Australia’ summary of the latest key HIV data and stats. The latest summary has just been released. Key points: Rapid uptake of PrEP, in combination with treatment as prevention, has led to declines in HIV notifications among Australian-born gay and bisexual men. Across the last six years, there has been a 44% decrease in HIV...
Information about TRUVADA and ATRIPLA delisting
Australian Federation of AIDS Organisations (AFAO), March 30th 2020 From 1 April 2020 Truvada for HIV treatment and for pre-exposure prophylaxis (PrEP) will no longer be available through the Pharmaceutical Benefits Scheme (PBS). There are alternatives to Truvada for PrEP in Australia. Community members eligible for PrEP can access generic versions of Truvada supplied by Apotex, Mylan and Lupin...